甲状腺乳头状癌BRAF^(V600E)基因突变与钠碘同向转运体表达的研究

BRAF mutation and sodium iodide symporter expression in papillary thyroid cancer

目的:探讨甲状腺乳头状癌(PTC)患者中BRAFV600E基因突变及钠碘同向转运体(NIS)蛋白的表达及两者间的相关性。方法:收集2008-01-01-2011-01-01青岛大学医学院附属医院病理科PTC石蜡包埋组织30例,其中癌旁组织为正常组织(G正常组)15例,癌旁组织为结节性甲状腺肿组织(G结甲组)15例。对PTC组织行DNA提取、PCR扩增、基因测序检测BRAFV600E基因突变,同时采用免疫组化的方法分析NIS蛋白表达,结果以免疫组化评分(IHS)表示。结果:30例PTC均无BRAFV600E基因突变;30例PTC组织中NIS蛋白表达,从0～12分,G正常组IHS=(7.92±3.01)分,G结甲组IHS=(6.58±2.71)分,两组NIS差异无统计学意义,t=1.11,P=0.95;BRAFV600E突变与NIS蛋白表达无相关性。结论:尚未发现癌旁不同的PTCBRAFV600E基因有突变及NIS蛋白表达的差异。BRAFV600E基因突变与NIS表达在PTC中的关系有待进一步研究。

OBJECTIVE： To investigate the BRAF gene mutation, sodium iodide symporter（NIS） expression and the relationship between the two above genes in papillary thyroid caner （PTC） patients. METHODS： Thirty PTC patients durning January 1, 2008 and January 1, 2011 in our hospital were enrolled in this study. Including PTC 15 cases with the surrounding normal tissue （G normal） and another PTC 15 cases with the surrounding nodular goiter tissue （G NG）. DNA was extracted from paraffin-embedded tumor specimens, and the presence of the BRAFV600Emutation was evaluated using PCR amplification and direct sequencing as well as tissue sections were subjected to immunohistochemistry （IH）. RESULTS： There was no BRAFV600E gene mu tations while NIS protein were expressed differently in 30 PTC cases from 0 point to 12 points. The expression of NIS in G normal [IHS=（7. 92±3. 01） points] and G NG 〈IHS=（6.58±2.71） points] have no significant value （t=1. 11, P=0.95）. There was no significant difference between BRAFV600E mutation and NIS expression in two groups. CONCLUSIONS： It＇s not found BRAFV600E mutation and NIS expression wariety in PTC with different surrounding tissue. The relationship of BRAFV600E mutation and NIS protein expression in papillary thyroid carcinoma need to be further studied.